- Home
- SEMR vs NVCR Comparison
SEMR vs NVCR Comparison
Compare SEMR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- NVCR
- Stock Information
- Founded
- SEMR 2008
- NVCR 2000
- Country
- SEMR United States
- NVCR Jersey
- Employees
- SEMR N/A
- NVCR N/A
- Industry
- SEMR EDP Services
- NVCR Medical/Dental Instruments
- Sector
- SEMR Technology
- NVCR Health Care
- Exchange
- SEMR Nasdaq
- NVCR Nasdaq
- Market Cap
- SEMR 1.7B
- NVCR 3.2B
- IPO Year
- SEMR 2021
- NVCR 2015
- Fundamental
- Price
- SEMR $11.73
- NVCR $29.99
- Analyst Decision
- SEMR Buy
- NVCR Buy
- Analyst Count
- SEMR 7
- NVCR 5
- Target Price
- SEMR $16.14
- NVCR $33.40
- AVG Volume (30 Days)
- SEMR 407.2K
- NVCR 1.1M
- Earning Date
- SEMR 11-07-2024
- NVCR 02-20-2025
- Dividend Yield
- SEMR N/A
- NVCR N/A
- EPS Growth
- SEMR N/A
- NVCR N/A
- EPS
- SEMR 0.08
- NVCR N/A
- Revenue
- SEMR $357,567,000.00
- NVCR $577,738,000.00
- Revenue This Year
- SEMR $24.50
- NVCR $19.13
- Revenue Next Year
- SEMR $20.36
- NVCR $5.38
- P/E Ratio
- SEMR $151.26
- NVCR N/A
- Revenue Growth
- SEMR 22.01
- NVCR 14.63
- 52 Week Low
- SEMR $9.64
- NVCR $11.70
- 52 Week High
- SEMR $16.42
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- SEMR 30.80
- NVCR 58.14
- Support Level
- SEMR $11.85
- NVCR $29.62
- Resistance Level
- SEMR $12.59
- NVCR $32.06
- Average True Range (ATR)
- SEMR 0.45
- NVCR 1.80
- MACD
- SEMR -0.13
- NVCR -0.60
- Stochastic Oscillator
- SEMR 12.59
- NVCR 8.20
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the provision of an online visibility management software-as-a-service platform. Its platform enables subscribers to improve their online visibility and drive traffic, including on their websites and social media pages, and distribute highly relevant content to their customers on a targeted basis across various channels to drive high-quality traffic and measure the effectiveness of their digital marketing campaigns. Geographically, it generates revenues from the US, the UK, and other regions.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.